Callan Family Office, LLC
Family OfficePosition in REGN — Regeneron Pharmaceuticals, Inc.
CIK 1938970
RADNOR, PA
Position in REGN
as of Jun 30, 2026
· filed Aug 11, 2026
Position Value
$6,321,448
-$660,127 QoQ
Shares Held
10,138
+12.2% QoQ
Ownership
0.010%
of shares outstanding
% of Portfolio
0.15%
of 13F equity value
Holder Rank
#357
of 1,322 holders
Holding Since
Mar 2023
8 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in REGN Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Callan Family Office, LLC holds $29,170,140 across 30 Biotechnology names. REGN ranks #2 (21.7% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
15,789 | $7,842,869 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
This page
|
10,138 | $6,321,448 | |
| 3 | ARGX |
Argenx SE
|
2,035 | $1,888,011 | |
| 4 | JAZZ |
Jazz Pharmaceuticals plc
|
7,722 | $1,860,770 | |
| 5 | TECH |
BIO-TECHNE Corp
|
22,045 | $1,557,479 | |
| 6 | GMAB |
Genmab A/S
|
55,033 | $1,511,756 | |
| 7 | INCY |
Incyte Corp
|
11,538 | $1,307,947 | |
| 8 | LGND |
Ligand Pharmaceuticals Inc
|
3,224 | $1,019,074 |
All Filings in REGN
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $6,321,448 | 10,138 | Shares | Sole | 2026-08-11 | |
| 2026-03-31 | $6,981,575 | 9,036 | Shares | Sole | 2026-05-13 | |
| 2025-12-31 | $7,017,842 | 9,092 | Shares | Sole | 2026-02-12 | |
| 2025-09-30 | $3,791,948 | 6,744 | Shares | Sole | 2025-11-04 | |
| 2025-06-30 | $3,171,000 | 6,040 | Shares | Sole | 2025-07-24 | |
| 2025-03-31 | $1,208,208 | 1,905 | Shares | Sole | 2025-05-13 | |
| 2024-12-31 | $1,117,645 | 1,569 | Shares | Sole | 2025-02-07 | |
| 2023-03-31 | $645,832 | 786 | Shares | Sole | 2023-05-12 | |
| No filing history on record for this holder in this stock. | ||||||